Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Kirsten rat sarcoma (KRAS) proteins are crucial in cell signaling, but mutations drive cancer, particularly nonsmall cell lung cancer (NSCLC).
• The KRAS protein's unique structure historically made it an 'undruggable' target for cancer therapies.
• Despite understanding KRAS function, effective precision medicine for KRAS-mutated NSCLC remained elusive.

Purpose of the Study:

• To review the development of KRAS inhibitors as precision medicines for NSCLC.
• To analyze historical attempts and current advancements in targeting KRAS mutations.
• To discuss future directions for KRAS inhibitor development and combination therapies.

Main Methods:

• Retrospective analysis of scientific literature on KRAS inhibitors.
• Review of preclinical and clinical investigations of KRAS-targeted drugs.
• Examination of combination strategies involving KRAS inhibitors and immune checkpoint inhibitors (ICIs).

Main Results:

• The development of AMG510, an orphan drug targeting KRASG12C, represents a major breakthrough.
• Multiple KRAS inhibitors are currently under investigation and development.
• Emerging evidence suggests NSCLC patients with KRAS mutations may benefit from ICIs, especially in combination therapies.

Conclusions:

• Significant progress has been made in developing KRAS inhibitors, moving from basic research to clinical applications.
• Combination therapies, particularly with ICIs, show promise for enhancing treatment efficacy in KRAS-mutated NSCLC.
• Continued research into KRAS inhibitors and their synergistic effects is crucial for advancing precision oncology.